Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2030
Global Microbiome Therapeutics Market to Reach $3. 9 Billion by 2030. Market Report Coverage – Microbiome Therapeutics. Market SegmentationNew York, Dec. 29, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2030” – https://www.reportlinker.com/p06001221/?utm_source=GNW • By Disease Type: Gastrointestinal and Infectious Diseases and Other Diseases • By Region: North America, Europe, Asia-Pacific, and Rest-of-the-World Regional Segmentation • North America – U.S., Canada • Europe – Germany, U.K., France, Sweden, and Rest-of-Europe • Asia-Pacific – China, Australia, Japan, India, and Rest-of-Asia-Pacific • Rest-of-the-World Growth Drivers • Increasing adoption of inorganic growth strategies in the market • Significant external funding for executing research and therapeutic innovation Market Challenges • Payer uncertainty and outcome-based pricing • Insufficient Application-Based Research Hindering Market Pull Market Opportunities • Entry of major players for the development of microbiome therapeutics • Growing eminence of microbiome therapeutics in cancer treatment Key Microbiome Therapeutics Companies Profiled 4D Pharma plc, AOBiome, Sanofi S.A, Ferring Pharmaceuticals, Finch Therapeutics, Immuron Limited, OxThera AB, among others Key Questions Answered in this Report: • What is microbiome therapeutics? How have different target therapy area settings for microbiome therapeutics evolved over the centuries? • What are the major market drivers, challenges, and opportunities in the global microbiome therapeutics market? • What was the global microbiome therapeutics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the expected market size in 2030? • How is each segment of the global microbiome therapeutics market expected to grow during the forecast period 2020-2030, and what is the estimated revenue expected to be generated by each of the segments by the end of 2030? • What are the developmental strategies implemented by the key players to sustain in the competitive market? • What is the growth potential of the global microbiome therapeutics in several countries globally? • Which target therapy area segment among the two gastrointestinal and infectious diseases and other therapy areas are offered or being developed by key players such as Taisho Pharmaceuticals, Immuron Limited, Sanofi S.A., and Rebiotix? • Which target therapy area segment led the market in 2019 and is expected to dominate the market in 2030, and why? • Which region dominated the global microbiome therapeutics market in 2019, and what are the anticipated trends from each of the regions in the forecast period 2020-2030? Market Overview Microbiome is defined as the collective genomes of the microbes (composed of fungi, bacteria, bacteriophage, viruses, and protozoa) that live inside and on the body. Clinical studies on various microbiomes have been significantly growing during the past decade, owing to the considerable reduction in the cost of DNA sequencing, enabling the microbes in their complex mixture to be defined by their genome. Research findings have generated information about the role of the microorganism population in determining human health. The microbiome is found to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others. Microbiome has become an attractive target for potential therapeutics owing to its extensive role in gastrointestinal and non-gastrointestinal diseases. However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results on the human health and microbial community are among such challenges. Several players, such as Sanofi S.A and Taisho Pharmaceuticals, are currently offering these microbiome therapeutics in the market. The entry of new players in the market, coupled with increased innovation pertaining to therapeutic output maximization with minimal side effects, has transformed the market currently. The existing market of microbiome therapeutics is favored by multiple factors, which include the rising geriatric populations coupled with the increased financing and the increasing adoption of inorganic growth strategies by key players in the market. Within the research report, the market is segmented on the basis of target therapy area (gastrointestinal and infectious diseases, and other diseases) and region (North America, Europe, Asia-Pacific, and Rest-of-the-World).This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain. Competitive Landscape Major players, including 4D Pharma, Enterome, and Finch Therapeutics, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, Asia-Pacific is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with soaring clinical activities pertaining to the development of microbiome therapeutics. Countries Covered • North America • U.S. • Canada • Europe • Germany • France • Sweden • U.K. • Rest-of-Europe • Asia-Pacific • China • India • Australia • Japan • Rest-of-Asia-Pacific • Rest-of-the-Word Read the full report: https://www.reportlinker.com/p06001221/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place. __________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Get the perfect dose of nostalgia with these Galaxy Buds Pro cases – Input
A little dash of old paired with something new can be a great touch to help you reconcile the contemporary with the classic. Samsung’s new Galaxy Buds Pro, which will run you about $200, just got that treatment now that the company has launched retro charging cases on sale. These cases are shaped after the nostalgic Anycall T100 and E700 and are available in select locations only. They weigh between 35g to 40g. But who cares about that? Depending on when you came of age, they’re worth their weight in nostalgia.
And that’s the downside to the news: the cases are available in South Korea as in-store items only. To be clear, the retro clamshell charging cases don’t work on their own, so don’t expect the clock to change the time accordingly or for the case to deliver messages or calls. Nope, none of that. The retro cases are more of an aesthetic addition to the Galaxy Buds Pro and it’s not clear how much battery capacity they actually come with. We expect Samsung to release more details in the coming days. Even then, a T100 or E700 cover sounds like a fun touch for $30 a pop.
Non-functional nostalgia — The purpose behind these T100 and E700 retro clamshell cases isn’t to provide any use. Samsung is pretty clear about this much, and it’s a detail that won’t offend consumers in all likelihood. This is all about nonfunctional nostalgia. The release of these retro cases is bound to resonate with consumers who once owned actual T100 and E700 cellphones… give or take 20 years ago. That crowd might just love it, though it is a bummer that Samsung has limited the sales of these cases to one country only.
Exclusivity is hot — For now, the cases remain on sale in South Korea alone. Maybe there are plans to bring the retro accessories to stores in the West — but that remains to be seen. In the meantime, while Samsung figures out the additional details for these cases (and we hope it lets western consumers but the T100 and E700 cases eventually), we’d love to know if you think Samsung’s Galaxy Buds Pro pose a legitimate threat to Apple’s AirPods Pro. All we know is the wireless earbuds war is far from over.
LG says it might quit the smartphone market – Ars Technica
As usual, things are not looking good for LG’s phone division. As reported by The Korea Herald, LG Electronics CEO Kwon Bong-Seok sent out a staff-wide memo that the company was considering making major changes to its smartphone division, including possibly quitting the smartphone business.
Last week, Korean news outlet TheElec also wrote about this memo in a now-deleted post. The post was deleted because LG brutally debunked the report, calling it “completely false and without merit.” This week, LG is confirming basically the same memo report from the Korea Herald, complete with comments from LG. The Verge also got a thumbs-up from LG about the report.
“Since the competition in the global market for mobile devices is getting fiercer, it is about time for LG to make a cold judgment and the best choice,” an LG official told the Korea Herald. “The company is considering all possible measures, including sale, withdrawal, and downsizing of the smartphone business.”
LG’s smartphone business has been suffering for a while. As the report points out, LG’s smartphone division lost about 5 trillion won ($4.5 billion) over the past five years. The official earnings count has the division at 22 consecutive money-losing quarters. Today you won’t find LG on a “Global smartphone market share” chart; instead, it will be buried down in the “other” category. In the US, Counterpoint has LG at 13 percent of the market, due mostly to pre-paid sales.
LG Electronics’ CEO only landed the position 13 months ago and has undoubtedly been evaluating LG’s only money-losing division over the past year. In an interview in January 2020, shortly after being appointed CEO, Kwon promised “LG Electronics’ mobile business is going to be profitable by 2021.” It’s still not clear if that’s considered a reasonable goal for the company.
TheElec’s original scoop is backed up and translated here. You should definitely take it with a grain of salt since the outlet deleted the post and isn’t standing behind it, but so far, it seems to be correct. It contains an interesting tidbit that’s not in the other report: that LG will announce a direction for its mobile unit on January 26. TheElec also claimed that LG sent out a directive to “stop all developments except for the i project,” with “i project” being a code name for LG’s flexible-display LG Rollable smartphone. The last bit of the report sounds very plausible in raising the possibility that the LG brand will never truly leave the smartphone market and will instead farm out the logo to various white-label ODM companies.
Why would anyone buy an LG phone?
LG has never had a solid sales pitch for the smartphone wars. At the high end of the market, LG has always seemed to be overshadowed by its bigger Korean rival, Samsung. It shipped high-spec phones with heavy Android skins and a bad update plan, and when Samsung offers the same thing with bigger brand recognition, why would anyone pick LG? At the low end of the market, especially in the US, the company has reliably shoveled cheap, anonymous phones into carrier stores and the pre-paid market. This is something that needs to be done, but again, there’s nothing here that would make LG stand out from the crowd.
If anything, LG has a pretty bad reputation when it comes to building smartphones. The company’s phones are known for dying early and going into “boot looping,” an unusable Android failure state where the phone reboots repeatedly due to bad flash memory. LG was sued over boot loops in 2017, with the lawsuit naming every high-profile LG device released in 2015 and 2016. LG ended up settling. I know I’ve personally laid four LG-made Google Nexus 5Xs to rest over boot loop issues.
When the company wasn’t occupying the same lane as Samsung, it was trotting out ridiculous gimmicks that would be forgotten a year or two later: there was the LG G5 with its modular accessories, like a clip-on camera grip; the inexplicably banana-shaped LG G Flex; and an obsession with various “dual screen” designs like the LG V10’s notification display, the LG V50’s clip-on second screen, and the LG Wing’s “T” shaped design. You can see the company trying to do something different to stand out, but none of these ideas was good, or at least they weren’t a hit with consumers.
Samsung announces Tab Active3 ruggedized Android tablet with removable battery – Notebookcheck.net
Ruggedized smartphones are fairly rare in today’s market, and rugged tablets are rarer still. There are still a few tough tablets out there, including a new device from Samsung.
The Tab Active3 is a new ruggedized Android tablet from Samsung. Featuring a 1.7 GHz octa-core processor (boost up to 2.7 GHz), 4 GB of RAM, and 64 GB of expandable storage, the 8-inch FHD+ tablet is powerful enough for most work-related tasks. It’s unlikely to win any gaming awards, but the Tab Active3 is designed for frontline workers who are often in difficult environments.
The Tab Active3 runs Android 10 and has a programmable button, S-Pen support, and NFC. The tablet also supports wireless DeX, Samsung’s pseudo-desktop feature that allows users to connect their Samsung device to a monitor and run a desktop version of the company’s One UI.
One of the most intriguing features is its removable 5050 mAh battery. The tablet can continue operation without a battery if it’s plugged into a wall, allowing users to (sort of) hot-swap batteries. Samsung has promised “up to three generations of Android OS upgrades.” Samsung doesn’t have the best track record when it comes to Android upgrades, so time will tell if the company keeps this promise. Samsung also promised up to 5 years of security updates.
The Samsung Tab Active3 starts at US$489.99 for a WiFi-only model (WiFi 6). An LTE model sells for $589.99.
COVID-19 variant identified at Barrie, Ont., long-term care home where 19 residents have died – CTV Toronto
Satellogic signs multi-launch contract with SpaceX – SpaceNews
Biden sworn in as president, calls on Americans to 'end this uncivil war' of political division – NBC News
Silver investment demand jumped 12% in 2019
Iran anticipates renewed protests amid social media shutdown
Galaxy M31 July 2020 security update brings Glance, a content-driven lockscreen wallpaper service
Sports12 hours ago
Three potential reasons why the Toronto Raptors have waived Alex Len – Raptors Rapture
Economy17 hours ago
Canadian dollar gains as stimulus hopes boost Wall Street
News18 hours ago
Biden intelligence pick favors ‘aggressive’ stance on China threat
Sports18 hours ago
Canadiens’ penalty killers simply perfect in Edmonton
News18 hours ago
Alibaba’s Jack Ma makes first public appearance in three months
Economy17 hours ago
China worries about lagging consumption as broader economy shakes off COVID – Financial Post
Tech17 hours ago
MediaTek taps TSMC 6-nanometer tech for new flagship 5G phone chips – Cape Breton Post
Sports20 hours ago
Report: Blue Jays still trying to sign outfielder Michael Brantley – Sportsnet.ca